Opendata, web and dolomites

NEOSETAC SIGNED

New Selenium-based Targeted Nanocapsules to treat Breast Cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "NEOSETAC" data sheet

The following table provides information about the project.

Coordinator
UNIVERSIDAD AUTONOMA DE BARCELONA 

Organization address
address: CALLE CAMPUS UNIVERSITARIO SN CERDANYOLA V
city: CERDANYOLA DEL VALLES
postcode: 8290
website: http://www.uab.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 504˙000 €
 EC max contribution 504˙000 € (100%)
 Programme 1. H2020-EU.1.3.3. (Stimulating innovation by means of cross-fertilisation of knowledge)
 Code Call H2020-MSCA-RISE-2017
 Funding Scheme MSCA-RISE
 Starting year 2018
 Duration (year-month-day) from 2018-01-01   to  2021-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSIDAD AUTONOMA DE BARCELONA ES (CERDANYOLA DEL VALLES) coordinator 171˙000.00
2    KAROLINSKA INSTITUTET SE (STOCKHOLM) participant 171˙000.00
3    ACIB GMBH AT (GRAZ) participant 54˙000.00
4    AB BCN S.L. ES (CERDANYOLA DEL VALLES) participant 45˙000.00
5    ADSI-AUSTRIAN DRUG SCREENING INSTITUTE GMBH AT (INNSBRUCK) participant 36˙000.00
6    REGION STOCKHOLM SE (STOCKHOLM) participant 27˙000.00
7    QUALIZYME DIAGNOSTICS GMBH & CO KG AT (GRAZ) participant 0.00

Map

 Project objective

The European Chronic Diseases Alliance has defined cancer as one of the major non-communicable diseases, accounting for 13% of the deaths worldwide, resulting in 8.2 million deaths annually. In the NEOSETAC project, breast cancer will be the focus of study being the most common cancers in women. It comprises of 10.4% of all the cancer incidences among women, causing 411 093 deaths per year overall the world. In Europe, there is more than twice of the amount of new breast cancer cases annually than new cases of cancer in any other place. The complexity of breast cancer makes it a big challenge for successful treatment. The NEOSETAC project will demonstrate the anti-cancer therapeutic potential of a novel Seleniumbased therapy for the management of breast cancer. The clinical application of Selenium (Se) compounds for cancer treatment is until now limited in chemoprevention as dietary supplement. In this proposal, we aim to improve the therapeutic window, pharmacokinetic properties and targeting drug delivery via nanoparticles (NPs). By loading Se into biodegradable NPs, drug release is controlled within the narrow therapeutic window of Se. At the same time the uptake and activation of Se compounds at desired location (tumor lesions and metastasis) is achieved. We also propose to functionalize NPs by cancer cell / cancer stem cell targeting ligands to further improve the therapeutic efficacy and prevent cancer recurrence after chemotherapy. These advantages will lead to an enhanced anticancer activity and reduced systemic toxicity. Moreover, targeting via NPs will improve the pharmacokinetic properties and increase the relatively short half-life (~18 hours) of Se.

 Deliverables

List of deliverables.
Dissemination and Communication Strategy defined including promotional kit Documents, reports 2020-03-18 18:53:26
Report of in vitro tests results and Se speciation of targeted nanosystems Documents, reports 2020-03-11 14:42:15

Take a look to the deliverables list in detail:  detailed list of NEOSETAC deliverables.

 Publications

year authors and title journal last update
List of publications.
2019 Viktorija Vidimce-Risteski
Flash Talk: [NEOSETAC]New Selenium-based Targeted Nanocapsules to treat Breast Cancer
published pages: , ISSN: , DOI:
European Summit of Industrial Biotechnology 2020-03-18
2018 María-Jesús Sánchez-Martín, Ying Zhao, Wenyi Zheng, Moustapha Hassan and Manuel Valiente
NEW SELENIUM-BASED NANOCAPSULES TO TREAT BREAST CANCER: NEOSETAC BACKGROUND
published pages: , ISSN: , DOI:
ONCO EMERGENCE FORUM BARCELONA 2018 2020-03-18
2019 Wenyi Zheng, Roberto Boada, Rui He, Tingting Xiao, Fei Ye, Laura Simonelli, Manuel Valiente, Ying Zhao, Moustapha Hassan
Extracellular Albumin Covalently Sequesters Selenocompounds and Determines Cytotoxicity
published pages: 4734, ISSN: 1422-0067, DOI: 10.3390/ijms20194734
International Journal of Molecular Sciences 20/19 2020-03-18
2019 Viktorija Vidimce-Risteski, Meritxell Galindo Casas, Wenyi Zheng, Claudia Tallian-Langer, Laura Teixidó Devesa, Iris H.Valido, Jorge Rodríguez-Martínez, Sandra Diez-García, Rui He, Lorena Sansegundo Barbosa, Simone Weinberger, Neus Sanchez Alberola,Ying Zhao, Maria-Jesús Sanchez-Martin, Doris Ribitsch, Michaela Preßnig, Moustapha Hassan and Manuel Valiente
Poster: NEOSETAC [ New Selenium-based Targeted Nanocapsules to treat Breast Cancer ]
published pages: , ISSN: , DOI:
European Summit of Industrial Biotechnology 2020-03-18

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEOSETAC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NEOSETAC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.3.)

VIRTUOUS (2019)

Virtual tongue to predIct the oRganoleptic profile of mediterranean IngredienTs and their effect on hUman hOmeostasis by means of an integrated compUtational multiphysicS platform

Read More  

BE-ARCHAEO (2019)

BEyond ARCHAEOlogy: an advanced approach linking East to West through science, field archaeology, interactive museum experiences

Read More  

RESEARCH (2018)

REmote SEnsing techniques for ARCHaeology

Read More